Agilent Technologies, Inc. (A) 股票分析

公司概述

Agilent Technologies, Inc. operates as a global provider of application-focused solutions within the life sciences, diagnostics, and applied chemical sectors, serving a broad international customer base. The company is categorized within the Healthcare sector and specifically functions in the Diagnostics & Research industry, positioning it as a critical supplier of analytical instruments and consumables for scientific research and clinical testing. In terms of scale, the firm commands a market capitalization of $32.64B and generates annual revenue of $7.06B, while employing approximately 18,000 personnel worldwide. These valuation and revenue figures indicate that Agilent holds a significant position in the specialized equipment market, reflecting a mature business model that balances substantial asset deployment with consistent cash generation capabilities in high-barrier-to-entry scientific markets.

财务健康

The company reported a trailing twelve-month revenue of $7.06B alongside net income of $1.29B and EBITDA of $1.97B, revealing a cost structure where operating expenses consume a significant portion of top-line growth before reaching the bottom line. The firm generated free cash flow of $855.88M, a metric that underscores strong financial flexibility by demonstrating the ability to fund capital expenditures, reduce debt, or return capital to shareholders without relying on external financing. Profitability analysis shows a gross margin of 52.3%, an operating margin of 22.9%, and a profit margin of 18.3%, indicating that the company retains over half of its revenue from core sales and effectively manages overhead to convert a substantial portion of gross profit into net earnings. On the balance sheet, the company holds $1.76B in cash against $3.55B in total debt, resulting in a debt-to-equity ratio of 51.39%, which suggests a leveraged capital structure that relies on equity financing to support its operations. Liquidity is robust, evidenced by a current ratio of 2.07, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities. Efficiency metrics further highlight management effectiveness with a return on equity of 19.9% and a return on assets of 8.5%, showing that the company generates nearly 20% returns on shareholder capital while maintaining a conservative asset utilization rate relative to its equity base.

估值评估

Valuation metrics for Agilent include a trailing P/E ratio of 25.47 and a forward P/E of 17.53, where the notable difference between these two figures implies that the market expects a significant contraction in earnings growth or a shift in profitability to normalize the valuation over the coming years. The price-to-book ratio stands at 4.72, indicating that the market values the company at a substantial premium over its net asset book value, likely reflecting intangible assets, brand strength, and proprietary technology that are not fully captured on the balance sheet. Alternative valuation measures such as a price-to-sales ratio of 4.62 and an EV/EBITDA of 17.45 provide additional context, suggesting that investors are willing to pay a high multiple relative to both revenue and earnings power, consistent with the capital-intensive nature of the diagnostics industry. Price action context is provided by a 52-week high of $160.27 and a 52-week low of $96.43, placing the current trading range within a wide band that suggests significant volatility and potential for mean reversion depending on market sentiment. Risk assessment is quantified by a beta of 1.30, which indicates that the stock's price volatility is 30% higher than the broader market, signaling that the asset will likely amplify market movements during periods of equity market turbulence.

Growth & Income

Growth dynamics are characterized by a revenue growth rate of 7.0% year-over-year contrasted with an earnings growth rate of -3.6% year-over-year, indicating that earnings are currently growing slower than revenue, which implies that cost pressures or margin compression are offsetting top-line expansion. As a dividend payer, the company offers a dividend yield of 0.9% with a payout ratio of 22.0%, suggesting that the dividend is highly sustainable given that the payout consumes less than a quarter of the generated earnings. This low payout ratio provides a buffer for the company to maintain or increase dividends even if earnings fluctuate, while the remaining earnings can be reinvested into research and development for future growth. Overall, the company presents a growth and income profile defined by steady revenue expansion, conservative dividend policy, and a valuation that reflects high expectations for future earnings recovery.